T cell receptor gamma variable 10 (non-functional)Genealiases: TCRGV10 · V3P
Q-omics provides the consensus-scored TRGV10 profile across patient tissues and cancer cell-line models. TRGV10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRGV10 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TRGV10 RNA expression shows 16,444 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, KIRC, and DLBC as cancer lineages where TRGV10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRGV10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRGV10 survival associations across molecular data types. TRGV10 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRGV10 RNA expression–survival associations across cancer types. High TRGV10 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, BLCA, UCS and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRGV10 RNA expression.
This table summarizes TRGV10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRGV10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRGV10 shows lower tumor expression in COAD, LUSC, THCA and LUAD and higher tumor expression in KIRC and PRAD. The KIRC box plot shows higher TRGV10 RNA expression in tumor versus normal tissue (log2 FC = +1.312, t-test p < 0.001).
This table shows molecular features associated with TRGV10 in patient tissues and cancer cell lines. In patient samples, TRGV10 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
